Mirtazapine Biogaran (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine and serotonin. It also antagonises 5‑HT2, 5‑HT3 and histamine H1 receptors, enhancing serotonergic activity while providing sedative and appetite‑stimulating effects.

The appropriate dose of mirtazapine is determined by the prescribing clinician based on the individual’s clinical condition, response, and tolerability. Dosage adjustments are made during treatment to achieve optimal therapeutic effect.

Mirtazapine is classified as a pregnancy category where use is only recommended if the potential benefit justifies the potential risk to the fetus. It is excreted in breast milk, so breastfeeding mothers should discuss risks and alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with selective serotonin reuptake inhibitors (SSRIs), mirtazapine often produces stronger sedative and appetite‑stimulating effects, which can be advantageous for patients with insomnia or weight loss. Its distinct receptor profile may result in a different side‑effect spectrum, making it a useful alternative when SSRIs are not tolerated.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original blister or container, protect from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Mirtazapine Biogaran is taken orally, usually once daily in the evening due to its sedative properties. Tablets should be swallowed whole with water and not chewed or crushed unless otherwise directed by a healthcare professional.

Serious risks include agranulocytosis, severe hepatic dysfunction, seizures, and rare cases of profound hypotension. Patients should be monitored for signs of infection, liver abnormalities, unexplained seizures or sudden drops in blood pressure, and seek immediate medical attention if these occur.

Mirtazapine is contraindicated in individuals who have taken a monoamine oxidase inhibitor within the past 14 days, those with known hypersensitivity to the drug, and patients with severe hepatic impairment. Caution is also advised for patients with a history of bipolar disorder, as it may precipitate mania.